MedPath

Heart Rate Variability (HRV)-Guided Transcranial Direct Current Stimulation (tDCS)

Not Applicable
Recruiting
Conditions
Depression
Interventions
Device: Sham Transcranial Direct Current Stimulation (tDCS)
Device: Active Transcranial Direct Current Stimulation (tDCS)
Registration Number
NCT06455527
Lead Sponsor
NYU Langone Health
Brief Summary

This technology development project will be informed and guided by initial data collection of human subject data. For this purpose, the investigators will recruit n=100 people with mild to moderate depression in a double-blinded, parallel-arm, sham-controlled data collection period administered at home and using the investigator's remotely supervised (RS) tDCS protocol. Enrolled participants will complete 10 days of 30-minute tDCS (2.0, DLPFC left anodal) using the RS-tDCS protocol. During each daily session, standard HR and impedance-based HR (i-HR), obtained from the tDCS headset, will be collected to identify a possible marker of response to tDCS in depression. Participants will be randomized 2:1 to active vs. sham tDCS.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Mild to moderate depression (Beck Depression Inventory(BDI)-II 14-28)
  • Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-V-TR) Depressive episode
  • Wide Range Achievement Test (WRAT)-4th Reading Recognition subtest standard score >85
Exclusion Criteria
  • Primary neurologic, psychiatric (e.g., multiple sclerosis, stroke, Parkinson's disease, spinal cord injury, intracranial mass, traumatic brain injury (TBI), epilepsy, mild cognitive impairment (MCI), or dementia), or major medical disorder (e.g., history of myocardial infarction, diabetes, thyroid disease, arrhythmia, atrial fibrillation) (medical history review)
  • DSM-V-TR bipolar depression, psychotic disorder, or alcohol or substance use disorder (M.I.N.I.)
  • Active or high suicidality risk (Columbia-Suicide Severity Rating Scale, C-SSRS), or otherwise judged as inappropriate by the study clinicians
  • History of a heart transplant, presence of permanent pacemaker implant or Left Ventricular Assist Device
  • Use of certain medications that can affect heart rate variability, such as beta-blockers, calcium channel blockers, or cardiac glycosides
  • Use of antidepressant, antipsychotic, anxiolytic, or stimulant medications
  • Pregnant or planning pregnancy during the study period
  • Seizure disorder or recent (<5 years) seizure history
  • Presence of metal objects in the head/neck
  • Any skin disorder or skin sensitive area near stimulation locations

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Sham tDCSSham Transcranial Direct Current Stimulation (tDCS)Participants randomized to the Active tDCS arm will complete 10 sessions of 30-minute sham RS-tDCS with chest strap and impedance-based HRV data collection over the course of approximately 2-4 weeks.
Active tDCSActive Transcranial Direct Current Stimulation (tDCS)Participants randomized to the Active tDCS arm will complete 10 sessions of 30-minute active remotely supervised (RS)-tDCS with chest strap and impedance-based HRV data collection over the course of approximately 2-4 weeks.
Primary Outcome Measures
NameTimeMethod
Average HR Measured Using i-HR Data LoggerUp to Week 4

HR will be measured using an impedance-based HR (i-HR) data logger attached to the Mini-CT tDCS device at each daily tDCS session.

Average Heart Rate (HR) Measured Using Polar H10 Chest MonitorUp to Week 4

HR will be measured using Polar H10 Chest Monitor at each daily tDCS session.

Secondary Outcome Measures
NameTimeMethod
Change in Positive and Negative Affect Schedule (PANAS-SF): Positive Affect ScoreBaseline, End of Intervention (Up to Week 4)

PANAS-SF is a self-report questionnaire that consists of two 10-item scales (20 items total) to measure both positive and negative affect. Each item is rated on a scale from 1 (very slightly or not at all) to 5 (extremely). The total positive affect score is the sum of affect item responses and ranges from 10 - 50; higher scores represent higher levels of positive affect.

Change in State-Trait Anxiety Inventory for Adults (STAI): Trait ScoreBaseline, End of Intervention (Up to Week 4)

STAI is a 40-item questionnaire measuring state and trait anxiety. Each item is rated on a 4-point Likert scale. The range of possible scores for trait anxiety ranges from a minimum score of 20 to a maximum score of 80; higher scores indicate greater trait anxiety.

Change in Montgomery Ӓsberg Depression Rating Scale (MADRS) ScoreBaseline, End of Intervention (Up to Week 4)

MADRS is a 10-item assessment of severity of depressive episodes in patients with mood disorders. Each item is rated on a scale from 0-6. The total score is the sum of responses and ranges from 0-60; higher scores indicate greater severity of depressive episodes.

Change in State-Trait Anxiety Inventory for Adults (STAI): State ScoreBaseline, End of Intervention (Up to Week 4)

STAI is a 40-item questionnaire measuring state and trait anxiety. Each item is rated on a 4-point Likert scale. The range of possible scores for state anxiety ranges from a minimum score of 20 to a maximum score of 80; higher scores indicate greater state anxiety.

Change in Positive and Negative Affect Schedule (PANAS-SF): Negative Affect ScoreBaseline, End of Intervention (Up to Week 4)

PANAS-SF is a self-report questionnaire that consists of two 10-item scales (20 items total) to measure both positive and negative affect. Each item is rated on a scale from 1 (very slightly or not at all) to 5 (extremely). The total negative affect score is the sum of negative item responses and ranges from 10 - 50; lower scores represent lower levels of negative affect.

Trial Locations

Locations (1)

NYU Langone Health

🇺🇸

New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath